Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navtemadlin, Cytarabine, and Idarubicin in Newly Diagnosed AML
NCT04190550Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2021
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of navtemadlin in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Primary endpoint: Incidence of adverse events. Started Feb 2021; status: active, not recruiting.
02
Drugs
navtemadlin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04190550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04190550.